| Ticker: CBST | 24 Emily Street | |
| Exchange: NASDAQ-National Market | Cambridge, Massachusetts 02139 | |
| Industry: Manufacturing | (617) 576-1999 |
| Type of Shares: | Common Shares | Filing Date: | 6/25/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 10/25/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $6.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.42 | |
| Offering Amount: | $30,000,000 | Selling: | $0.25 | |
| Expenses: | $600,000 | Reallowance: | $0.10 | |
| Shares Out After: | 9,133,921 |
| Manager | Tier | Phone |
| UBS Securities Inc. | Lead Manager | (212) 230-4000 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 576-3423 |
| Pacific Crest Securities Inc. | Co-manager | (503) 248-0721 |
| Auditor: Coopers & Lybrand | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $1.27 | $2.05 | $0.10 | Assets: | $10.36 |
| Net Income: | -$5.40 | -$2.07 | -$3.32 | Liabilities: | $3.57 |
| EPS: | $0.93 | -$0.33 | Equity: | $6.79 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a biopharmaceutical company engaged in the research, development and commercialization of novel antiinfective drugs to treat infectious diseases caused by bacteria and fungi, primarily those resistant to existing antiinfective drugs. The increasing prevalence of drug-resistant bacterial and fungal pathogens has led to significantly higher mortality rates from infectious diseases and currently presents a serious crisis worldwide. Cubist's strategy for combating antiinfective drug resistance is to identify novel intracellular targets essential for cell function in bacteria and fungi, such as proteins, RNA or DNA, which if inhibited by a drug would kill or attenuate the growth of the pathogen. The company selects these targets based on a thorough understanding of their function, thereby providing a foundation for assay development and identification of leads for drug discovery. The company believes that its rational, target-based, drug discovery strategy represents a distinct departure from and offers significant advantages over traditional drug discovery strategies to counter resistance. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for research and development, working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.